Anakinra is a recombinant human IL-1Ra that competitively inhibits IL-1α and IL-1β interaction with IL-1R1 and is currently indicated for the treatment of refractory RA and for CAPS (Cryopyrin Associated Periodic Syndrome) (Cavalli and Dinarello, 2015). This evidence concerns the gene IL1B and cryopyrin-associated periodic syndrome.